Gan to kagaku ryoho. Cancer & chemotherapy · 2025
[Efficacy and Safety of R‒mini‒CHP Combined with Polatuzumab‒Vedotin Used for Previously Untreated Diffuse Large B‒Cell Lymphoma in Very Elderly Patients Aged ≥80 Years-A Single‒Center Retrospective Analysis].
Аннотация на английскомСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Sekiguchi Yasunobu, Tsutsumi Hiroki, Kudo Masahisa, Hamano Shizuka, Arai Kosuke, Maseki Nobuo, Iizaki Yoshie, Kawamura Machiko, Kobayashi Kazuhiko, Nishimura Yu, Kanda Hiroaki, Takei Daisuke, Abe Tomoya, Hanai Makoto, Kakusaka Yu, Endo Sayaka, Nakayama Toshiaki, Shimano Yasumasa, Kobayashi Hirofumi
Аннотация
OBJECTIVE: We retrospectively evaluated the efficacy and safety of Pola‒R‒mini‒CHP therapy administered to very elderly treatment‒naive patients with DLBCL at our institution and compared them with R‒mini‒CHOP therapy reported from previous prospective studies.
MATERIALS AND METHODS: We retrospectively analyzed the data of 23 patients. The median age of the patients was 83 (range 80‒92) years. The median observation period was 8.9 (3‒22) months, and the median number of treatment cycles was 8 (2‒8).
RESULTS: The treatment was completed in 15 of the 23 patients, discontinued in 3 (1 died), and was ongoing in 5. The complete response rate (CRR) was 100% and the cumulative survival rate was 94.7%. In regard to hematological adverse events (Hem‒AEs), ≥Grade (G) 3 events occurred in 12 (52.2%), including anemia in 4 (17.4%), neutropenia in 4 (17.4%), leukopenia in 3 (13.0%), and thrombocytopenia in 1 (4.3%). In regard to non‒Hem‒AEs, ≥G3 events occurred in 3 (13.0%), including G3 COVID‒19 (coronavirus infectious disease) pneumonia and G3 bacteremia in 1 (4.3%) each; other non‒Hem‒AEs were G5 interstitial pneumonia in 1 (4.3%), ≤G2 constipation in 5 (21.7%), and ≤G2 peripheral neuropathy and ≤G2 diarrhea in 1 (4.3%) each.
CONCLUSION: The results suggest that Pola‒R‒mini‒CHP was more effective and safer than R‒mini‒CHOP therapy. Comparison of the adverse events revealed that the incidence of anemia was higher, incidence of infection was comparable, and the incidences of gastrointestinal toxicity and peripheral neuropathy were lower in the patients who received Pola‒R‒mini‒CHP therapy as compared with R‒mini‒CHOP therapy. It was possible to continue as an outpatient.
MATERIALS AND METHODS: We retrospectively analyzed the data of 23 patients. The median age of the patients was 83 (range 80‒92) years. The median observation period was 8.9 (3‒22) months, and the median number of treatment cycles was 8 (2‒8).
RESULTS: The treatment was completed in 15 of the 23 patients, discontinued in 3 (1 died), and was ongoing in 5. The complete response rate (CRR) was 100% and the cumulative survival rate was 94.7%. In regard to hematological adverse events (Hem‒AEs), ≥Grade (G) 3 events occurred in 12 (52.2%), including anemia in 4 (17.4%), neutropenia in 4 (17.4%), leukopenia in 3 (13.0%), and thrombocytopenia in 1 (4.3%). In regard to non‒Hem‒AEs, ≥G3 events occurred in 3 (13.0%), including G3 COVID‒19 (coronavirus infectious disease) pneumonia and G3 bacteremia in 1 (4.3%) each; other non‒Hem‒AEs were G5 interstitial pneumonia in 1 (4.3%), ≤G2 constipation in 5 (21.7%), and ≤G2 peripheral neuropathy and ≤G2 diarrhea in 1 (4.3%) each.
CONCLUSION: The results suggest that Pola‒R‒mini‒CHP was more effective and safer than R‒mini‒CHOP therapy. Comparison of the adverse events revealed that the incidence of anemia was higher, incidence of infection was comparable, and the incidences of gastrointestinal toxicity and peripheral neuropathy were lower in the patients who received Pola‒R‒mini‒CHP therapy as compared with R‒mini‒CHOP therapy. It was possible to continue as an outpatient.